Claims for Patent: 10,220,076

Summary for Patent: 10,220,076

Title:	Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
Abstract:	Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
Inventor(s):	Morales; Mercedes (San Jose, CA), Imran; Mir (Los Altos Hills, CA), Korupolu; Radhika (San Jose, CA), Hashim; Mir (Fremont, CA)
Assignee:	InCube Labs, LLC (San Jose, CA)
Application Number:	14/714,146
Patent Claims:	1. A shaped mass comprising insulin, the shaped mass formed by compression of a precursor material comprising insulin, wherein at least about 80% of the insulin in the shaped mass is biologically active, the shaped mass having a density in a range of about 0.95 to about 1.15 mg/mm.sup.3, and wherein the weight percentage of insulin in the shaped mass is in a range of about 80% to 95%, wherein the shaped mass comprises a pharmaceutical excipient. 2. The shaped mass of claim 1, wherein the density is in a range of about 0.98 to about 1.10 mg/mm.sup.3. 3. The shaped mass of claim 1, wherein at least about 95% of the insulin in the shaped mass is biologically active. 4. The shaped mass of claim 1, wherein the shaped mass comprises between about 0.2 to about 0.8 mg of insulin. 5. The shaped mass of claim 1, wherein the insulin comprises human insulin. 6. The shaped mass of claim 1, wherein the compression is performed in a mold. 7. The shaped mass of claim 1, wherein the shaped mass is formed by compression of a powder comprising insulin. 8. The shaped mass of claim 1, wherein the shaped mass has a pellet or cylindrical shape. 9. The shaped mass of claim 1, wherein the shaped mass has a tablet shape. 10. The shaped mass of claim 1, wherein the shaped mass has a tissue penetrating shape. 11. The shaped mass of claim 1, wherein the shaped mass comprises a biodegradable material which breaks down in a wall of a small intestine so as to release the insulin. 12. The shaped mass of claim 1, wherein the pharmaceutical excipient comprises at least one of a lubricant, a binding agent, a bulking agent or PEG. 13. The shaped mass of claim 12, wherein the binder is povidone. 14. The shaped mass of claim 12, wherein the bulking agent is mannitol. 15. The shaped mass of claim 12, wherein the lubricant is PEG. 16. The shaped mass of claim 12, wherein the lubricant is PEG, the bulking agent is mannitol and the binder is povidone. 17. A shaped mass comprising insulin, wherein: i) at least about 80% of the insulin in the shaped mass is biologically active; ii) the shaped mass has a density in a range of about 0.95 to about 1.15 mg/mm.sup.3; iii) the weight percentage of insulin in the shaped mass is in a range of about 80% to 95%; and; iv) the shaped mass degrades in a tissue to release insulin into a bloodstream to treat a blood glucose regulation disorder, and wherein the shaped mass comprises a pharmaceutical excipient. 18. The shaped mass of claim 17, wherein the tissue is an intestinal tissue or an intestinal wall tissue. 19. The shaped mass of claim 18, where the intestinal wall is a wall of a small intestine. 20. The shaped mass of claim 17, wherein the tissue is an intramuscular tissue. 21. The shaped mass of claim 17, wherein the density is in a range of about 0.98 to about 1.10 mg/mm.sup.3. 22. The shaped mass of claim 17, wherein the blood glucose regulation disorder is diabetes. 23. The shaped mass of claim 17, wherein the shaped mass comprises about 0.2 to about 0.8 mg of insulin. 24. The shaped mass of claim 17, wherein the insulin comprises human insulin.

Details for Patent 10,220,076

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982		2034-05-15
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015		2034-05-15
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998		2034-05-15
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994		2034-05-15
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018		2034-05-15
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 25, 1991		2034-05-15